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participate.Current Status of Rotational Atherectomy 345Matthew I. Tomey, Annapoorna S. Kini, Samin K. Sharma
Rotational atherectomy (RA) facilitates procedural and angiographic success in
percutaneous coronary intervention of complex, rigid lesions, particularly those
affected by severe calciﬁcation. Evidence for long-term reduction in restenosis and
major adverse cardiovascular events, however, is lacking. We review RA technique,
safety, and efﬁcacy data in the era of drug-eluting stents, strategies to prevent and
manage complications, including slow-ﬂow/no-reﬂow and burr entrapment; and
appropriate use in the context of broader evolution in management of stable
ischemic heart disease.Clinical Research Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus
Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left
Main Coronary Artery From the DELTA Registry: A Multicenter Registry Evaluating
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for
Left Main Treatment354Toru Naganuma, Alaide Chieffo, Emanuele Meliga, Davide Capodanno, Seung-Jung Park,
Yoshinobu Onuma, Marco Valgimigli, Sanda Jegere, Raj R. Makkar, Igor F. Palacios,
Charis Costopoulos, Young-Hak Kim, Piotr P. Buszman, Tarun Chakravarty, Imad Sheiban,
Roxana Mehran, Christoph Naber, Ronan Margey, Arvind Agnihotri, Sebastiano Marra,
Piera Capranzano, Martin B. Leon, Jeffrey W. Moses, Jean Fajadet, Thierry Lefevre,
Marie-Claude Morice, Andrejs Erglis, Corrado Tamburino, Ottavio Alﬁeri, Patrick W. Serruys,
Antonio Colombo
This study compared clinical outcomes after percutaneous coronary intervention
(PCI) with drug-eluting stents (DES) (n ¼ 482) versus coronary artery bypass graft
(CABG) (n ¼ 374) for ostial/midshaft lesions in an unprotected left main coronary
artery (ULMCA). At 1,293 days, there were no signiﬁcant differences in the
propensity score–adjusted analyses for the composite endpoint of all-cause death,
myocardial infarction, and cerebrovascular accident and major adverse cardiac and
cerebrovascular events. However, a higher incidence of target vessel revasculariza-
tion was observed in the PCI compared with the CABG group, with a trend toward
higher target lesion revascularization. In conclusion, this study demonstrates that
PCI for ostial/midshaft lesions in a ULMCA is associated with clinical outcomes
comparable to those observed with CABG at long-term follow-up, despite the use
of older, ﬁrst-generation DES.
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A-21Mortality in South Asians and Caucasians After Percutaneous Coronary Intervention
in the United Kingdom: An Observational Cohort Study of 279,256 Patients From
the BCIS (British Cardiovascular Intervention Society) National Database362Daniel A. Jones, Sean Gallagher, Krishnaraj S. Rathod, Simon Redwood, Mark A. de Belder,
Anthony Mathur, Adam D. Timmis, Peter F. Ludman, John N. Townend, Andrew Wragg,
on behalf of the NICOR (National Institute for Cardiovascular Outcomes Research)
This study investigated the impact of ethnicity on mortality after percutaneous
coronary intervention (PCI) in a national patient cohort. A total of 279,256 patients
underwent PCI, of whom 259,318 (92.9%) were Caucasian and 19,938 (7.1%) were
South Asian. South Asians were younger and had more extensive disease and major
risk factors, particularly diabetes. Unadjusted mortality rates were lower for South
Asians compared with Caucasians. Age-adjusted analysis revealed increased
mortality (hazard ratio: 1.24; 95% conﬁdence interval: 1.18 to 1.30) but with no
difference after adjustment (hazard ratio: 0.99; 95% conﬁdence interval: 0.94 to
1.05). In South Asians, high diabetes rates exert an adverse inﬂuence on mortality,
but ethnicity itself is not an independent outcome predictor.Impact of Cigarette Smoking on Extent of Coronary Artery Disease and Prognosis
of Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: An
Analysis From the ACUITY Trial (Acute Catheterization and Urgent Intervention
Triage Strategy)372Jason O. Robertson, Ramin Ebrahimi, Alexandra J. Lansky, Roxana Mehran, Gregg W. Stone,
A. Michael Lincoff
This study evaluated outcomes for smokers with moderate- to high-risk non–ST-
segment elevation acute coronary syndromes (NSTE-ACS) from the 13,819-
patient ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy)
trial. Smoking has been associated with the “paradox” of reduced mortality after
acute myocardial infarction (MI). In contrast to the paradox previously described in
ST-segment elevation MI, our analysis ﬁnds smoking to be an independent
predictor of higher 1-year mortality in patients presenting with NSTE-ACS
(hazard ratio: 1.37, 95% conﬁdence interval: 1.07 to 1.75; p ¼ 0.013), and our
angiographic study demonstrates coronary artery disease in smokers that is
comparable to that in nonsmokers but evident w1 decade earlier.EDITORIAL COMMENTImpact of Smoking Status in Patients With Non–ST-Segment Elevation Myocardial
Infarction: The Reverse Smoker’s Paradox380Jorge A. Belardi(continued on A-22)
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A-22Efﬁcacy of a Minicourse in Radiation-Reducing Techniques in Invasive Cardiology:
A Multicenter Field Study382Eberhard Kuon, Kerstin Weitmann, Wolfgang Hoffmann, Marcus Dörr, Thorsten Reffelmann,
Astrid Hummel, Alexander Riad, Mathias C. Busch, Klaus Empen, Stephan B. Felix
In a representative multicenter ﬁeld study, an educational 90-min minicourse
in lower-irradiating invasive techniques signiﬁcantly (p < 0.001) reduced patients’
median values due to coronary angiography as follows: overall dose area product
(DAP) (–48.4%: from baseline 26.5 to 13.7 Gy  cm2); ﬂuoroscopy times
(–20.8%); radiographic runs (–9.1%); frames/run (–18.6 %); frames (–29.6%);
radiographic DAP/frame (–27.4%); and ﬂuoroscopic DAP/s (–39.3%). Multilevel
analysis (p < 0.001) revealed higher DAP for male sex, increasing body mass index
and age, anddowing to different settings during image acquisitiondfor advanced
versus older catheterization systems.EDITORIAL COMMENTMandatory Radiation Safety Training for Fluoroscopy Imaging:
A Quality Improvement Priority or Unnecessary Oversight?391Charles E. ChambersSTRUCTURAL
Clinical ResearchMitraClip Therapy in Surgical High-Risk Patients: Identiﬁcation of Echocardiographic
Variables Affecting Acute Procedural Outcome394Edith Lubos, Michael Schlüter, Eik Vettorazzi, Britta Goldmann, Daniel Lubs,
Johannes Schirmer, Hendrik Treede, Hermann Reichenspurner, Stefan Blankenberg,
Stephan Baldus, Volker Rudolph
Acute procedural failure of MitraClip therapy was encountered in 32 (10.7%) of
300 consecutively treated surgical high-risk patients (age 75  9 years, 190 [63%]
men). Exact logistic regression analyses identiﬁed mean transmitral pressure
gradient (TMPG), effective regurgitant oriﬁce area (EROA), and mitral valve
oriﬁce area (MVOA) as independent predictors of acute procedural failure. Clas-
siﬁcation tree analysis revealed that an EROA >70.8 mm2 was associated with
a 25% rate of “clip failure” (inadequate MR reduction despite MitraClip im-
plantation), whereas the presence of both an MVOA 3.0 cm2 and a TMPG 4
mm Hg was associated with a 37.5% rate of aborted procedures (no clip implanted).
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A-23Effect of Catheter-Based Patent Foramen Ovale Closure on the Occurrence of
Arterial Bubbles in Scuba Divers403Jakub Honek, Martin Srámek, Ludek Sefc, Jaroslav Januska, Jirí Fiedler, Martin Horváth,
Ales Tomek, Stepán Novotný, Tomás Honek, Josef Veselka
Patent foramen ovale (PFO) is a risk factor of decompression sickness in divers due
to paradoxical embolization of bubbles. To date, the effectiveness of catheter-based
PFO closure in divers has not been demonstrated. A total of 47 divers with PFO
(PFO group) or after a catheter-based PFO closure (closure group) were examined
after a simulated dive. Venous and arterial bubbles were detected sonographically.
Catheter-based PFO closure was associated with the complete elimination of
arterial bubbles. This suggests its potential role in the prevention of unprovoked
decompression sickness recurrence in divers.EDITORIAL COMMENTThe PFO Gets Blamed Again.Perhaps This Time it Is Real 409Alfred A. BovePERIPHERAL
Clinical ResearchDrug-Eluting Balloons for the Treatment of the Superﬁcial Femoral Artery
In-Stent Restenosis: 2-Year Follow-Up411Vittorio Virga, Eugenio Stabile, Giancarlo Biamino, Luigi Salemme, Angelo Cioppa,
Giuseppe Giugliano, Tullio Tesorio, Linda Cota, Grigore Popusoi, Armando Pucciarelli,
Giovanni Esposito, Bruno Trimarco, Paolo Rubino
The use of drug-eluting balloons (DEBs) for the treatment of superﬁcial femoral
artery (SFA) in-stent restenosis (ISR) is associated with a satisfactory primary
patency rate at 1 year, but no data are available for longer follow-up. The aim of this
prospective registry was to evaluate safety/efﬁcacy of the use of DEBs for the
treatment of SFA ISR at 2 years. During follow-up, the primary patency rate at
2 years was 70.3 %. The data suggest that adjunctive use of DEBs for the treatment
of SFA ISR is a safe and effective therapeutic strategy up to 2 years of follow-up.Comparison Between Covered and Bare Cheatham-Platinum Stents for
Endovascular Treatment of Patients With Native Post-Ductal Aortic Coarctation:
Immediate and Intermediate-Term Results416Bahram Sohrabi, Peiman Jamshidi, Alireza Yaghoubi, Afshin Habibzadeh,
Yashar Hashemi-aghdam, Araz Moin, Babak Kazemi, Samad Ghaffari,
Mohammad Reza Abdolahzadeh Baghayi, Khalil Mahmoody
In this randomized clinical trial, we compared outcome of stenting with bare or
covered Cheatham-Platinum stents in severe native coarctation of aorta patients.
Both groups had 100% success, with remarkable effects on hemodynamic status.
During follow-up, the rate of recoarctation and pseudoaneurysm formation was
quite low. These ﬁndings indicate that coarctation of aorta stenting is a safe
procedure.EDITORIAL COMMENTCovered Stents for Coarctation of the Aorta: Treating the Interventionalist
or the Patient?424Ziyad M. Hijazi, Damien P. Kenny(continued on A-24)
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A-24PHARMACODYNAMICS
Clinical ResearchPharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor–Mediated
Signaling in Prasugrel-Treated Patients426Fabiana Rollini, Francesco Franchi, Antonio Tello-Montoliu, Ronakkumar Patel,
Andrew Darlington, José Luis Ferreiro, Jung Rae Cho, Ana Muñiz-Lozano, Bhaloo Desai,
Martin M. Zenni, Luis A. Guzman, Theodore A. Bass, Dominick J. Angiolillo
Variability in prasugrel pharmacodynamic effects has been shown, particularly in
high-risk settings. Cangrelor is a potent intravenous P2Y12 receptor inhibitor. We
assessed the in vitro P2Y12 receptor inhibitory effects of cangrelor on platelets from
patients on maintenance prasugrel therapy treated with 2 reloading dose regimens
(30 mg or 60 mg). In the absence of cangrelor, prasugrel reloading signiﬁcantly
reduced platelet reactivity index (PRI). Cangrelor was overall associated with further
P2Y12 receptor inhibitory effects. In patients reloaded with prasugrel 30 mg, can-
grelor decreased PRI at each time point. In patients reloaded with prasugrel 60 mg,
cangrelor decreased PRI at baseline and 1 h, but not at 4 h.
JACC: Cardiovascular Interventions CME is available online.
Go to http://interventions.onlinejacc.org/ to participate.Pharmacodynamic Effects During the Transition Between Cangrelor and
Ticagrelor435David J. Schneider, Zubin Agarwal, Naveen Seecheran, Friederike K. Keating, Prospero Gogo
Because consistent antiplatelet effects are advantageous after coronary intervention,
we assessed pharmacodynamic effects during transition between 2 reversible P2Y12
antagonists, cangrelor and ticagrelor. Participants (n ¼ 12) with stable coronary
artery disease on aspirin 81 mg daily received a bolus plus infusion of cangrelor on
study day 1 and were given a loading dose of ticagrelor (180 mg) during the
infusion. Participants took ticagrelor for 3 days and then stopped either 12 or 24 h
before a second bolus plus infusion of cangrelor. Ticagrelor can be administered
before, during, or after treatment with cangrelor without signiﬁcantly affecting
antiplatelet effects of either agent.(continued on A-25)
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A-25IMAGES IN
INTERVENTIONAlcohol Ablation of Right Ventricular Outﬂow Tract Obstruction 443Sivasubramanian Ramakrishnan, Balram Bhargava, Sandeep Seth, Balram Airan
This article has accompanying videos that can be viewed in the online version
of this issue.In-Stent Thin-Cap Fibroatheroma After Drug-Eluting Stent Implantation:
Ex-Vivo Evaluation of Optical Coherence Tomography and Intracoronary
Angioscopy446Kenichi Fujii, Hiroyuki Hao, Takahiro Imanaka, Taro Kawano, Tadateru Takayama,
Atsushi Hirayama, Tsutomu Yamada, Hatsue Ishibashi-Ueda, Seiichi Hirota, Tohru MasuyamaSuccessful Transcatheter Aortic Valve Replacement in
a Patient With a Sinus of Valsalva Aneurysme29Cara Hendry, Anthony Della Siega, Imad J. Nadra, Simon D. RobinsonFollow-Up Improvement of Distal Vessel Diameter After
Successful Chronic Total Coronary Occlusion Recanalizatione31Gabriele L. Gasparini, Marco L. Rossi, Patrizia PresbiteroSelf-Expanding Stent Peeling Away From Overlapping
Balloon-Expandable Stent Causing Late Acquired Aneurysm Formation and Stent
Malappositione35Chi Yuen Chan, Eugene B. Wu, Bryan P. Yan
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A-26LETTERS TO
THE EDITORPlatelet Reactivity Is Preferred Over Genotyping in Monitoring Efﬁcacy of
Antiplatelet Therapy448Nicoline J. Breet, Jurrien M. ten BergREPLYChiara Viviani Anselmi, Carlo Briguori, Roberta Roncarati, Laura Papa, Gabriella Visconti,
Amelia Focaccio, Francesca De Micco, Michael V. G. Latronico, Paolo Pagnotta,
Gianluigi CondorelliEDITOR’S PAGE Is Participation in Clinical Research a Duty? 450Spencer B. King III
